Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Novo Nordisk (NVO - Analyst Report) is conducting a cardiovascular (CV) outcomes trial, LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), aiming to assess and confirm the cardiovascular safety of Victoza. Results from the study should be out in 2016. Enrolment, which completed in Apr 2012, exceeded the original target by 586 patients.

We note that Victoza is a once-daily human GLP-1 analogue approved for improving blood sugar levels in adult type II diabetes patients. Revenues from Victoza were DKK 5.6 billion in the first half 2013, up 30% year over year (up 32% in local currencies). Victoza commanded a global market share of 69% in the GLP-1 segment at the end of May 2013 compared with 64% a year ago. Since Victoza’s launch, the GLP-1 market has expanded in the U.S.

Novo Nordisk has, in the meanwhile, completed all four trials under the SCALE phase IIIa study for Victoza 3 mg as a treatment for obesity. The company expects to file for approval in the U.S. and EU around the turn of the year.

Novo Nordisk has two more type II diabetes drugs – Tresiba and Ryzodeg – in its portfolio. While these drugs are approved in the EU and Japan, U.S. approval is yet to come. The FDA has asked Novo Nordisk to conduct a dedicated CV outcomes study for both Tresiba and Ryzodeg before it grants approval. Novo Nordisk expects to start the study later this year.

Many other companies have also conducted or are conducting cardiovascular outcomes study for diabetes drugs including Onglyza, Tradjenta, Lyxumia and Nesina.

Novo Nordisk currently carries a Zacks Rank #2 (Buy). Other large cap pharma stocks that look well-placed include Roche Holding (RHHBY - Analyst Report)), Eli Lilly and Company (LLY - Analyst Report) and Bayer (BAYRY - Analyst Report)). Roche carries a Zacks Rank #1 (Strong Buy) while Bayer and Eli Lilly carry a Zacks Rank #2.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%